1-12 of 12
Youngchul Song
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

Jennifer L. Cotton, Javier Estrada Diez, Vivek Sagar, Julie Chen, Michelle Piquet, John Alford, Youngchul Song, Xiaoyan Li, Markus Riester, Matthew T. DiMare, Katja Schumacher, Gaylor Boulay, Kathleen Sprouffske, Lin Fan, Tyler Burks, Leandra Mansur, Joel Wagner, Hyo-eun C. Bhang, Oleg Iartchouk, John Reece-Hoyes, Erick J. Morris, Peter S. Hammerman, David A. Ruddy, Joshua M. Korn, Jeffrey A. Engelman, Matthew J. Niederst
Journal: Cancer Research
Cancer Res (2023) 83 (21): 3611–3623.
https://doi.org/10.1158/0008-5472.CAN-23-0144
Published: 01 November 2023
View article titled, Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
Open the PDF for Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance in another window
Includes: Supplementary data
Journal Articles

Abstract PO-100: Expressed molecular barcoding coupled with single cell RNAseq enables a high resolution investigation into the evolution of drug tolerance

Jennifer L. Cotton, Viveksagar Krisnamurthy Radhakrishna, Javier Estrada Diez, David A. Ruddy, Kathleen Sprouffske, Gaylor Boulay, Michelle Piquet, Joel Wagner, Youngchul Song, Xiaoyan Li, Katja Schumacher, Joshua Korn, Erick J. Morris, Peter S. Hammerman, Jeffrey A. Engelman, Matthew J. Niederst
Journal: Cancer Research
Cancer Res (2020) 80 (21_Supplement): PO-100.
https://doi.org/10.1158/1538-7445.TUMHET2020-PO-100
Published: 03 November 2020
View article titled, Abstract PO-100: Expressed molecular barcoding coupled with single cell RNAseq enables a high resolution investigation into the evolution of drug tolerance
Journal Articles

Abstract 5008: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation

Gino B. Ferraro, David P. Kodack, Vasileios Askoxylakis, Qing Sheng, Mark Badeaux, Shom Goel, Xiaolong Qi, Ram Shankaraiah, Alexander Z. Cao, Rakesh R. Ramjiawan, Divya Bezwada, Bhushankumar Patel, Youngchul Song, Carlotta Costa, Kamila Naxerova, Christina Wong, Jonas Kloepper, Rita Das, Angela Tam, Jantima Tanboon, Dan G. Duda, Ryan C. Miller, Marni B. Siegel, Carey K. Anders, Melinda Sanders, Valeria M. Estrada, Robert Schlegel, Carlos L. Arteaga, Elena Brachtel, Alan Huang, Dai Fukumura, Jeffrey A. Engelman, Rakesh K. Jain
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5008.
https://doi.org/10.1158/1538-7445.AM2017-5008
Published: 01 July 2017
View article titled, Abstract 5008: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation
Journal Articles

Abstract 783: Ponatinib demonstrates antitumor activity in RET- and FGFR-driven patient-derived xenografts

Joseph M. Gozgit, Youngchul Song, Victor M. Rivera
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 783.
https://doi.org/10.1158/1538-7445.AM2015-783
Published: 01 August 2015
View article titled, Abstract 783: Ponatinib demonstrates antitumor activity in RET- and FGFR-driven patient-derived xenografts
Journal Articles

Abstract 2619: Meausuring PIP3 reveals the unexpected role of p110B in luminal breast cancers

Carlotta Costa, Hiromichi Ebi, Anthony C. Faber, Madhuri Nishtala, Youngchul Song, Cyril H. Benes, Jeffrey A. Engelman
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 2619.
https://doi.org/10.1158/1538-7445.AM2014-2619
Published: 01 October 2014
View article titled, Abstract 2619: Meausuring PIP3 reveals the unexpected role of p110B in luminal breast cancers
Journal Articles

Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition

Ryohei Katayama, Aki Aoyama, Takao Yamori, Jie Qi, Tomoko Oh-hara, Youngchul Song, Jeffrey A. Engelman, Naoya Fujita
Journal: Cancer Research
Cancer Res (2013) 73 (10): 3087–3096.
https://doi.org/10.1158/0008-5472.CAN-12-3256
Published: 12 May 2013
View article titled, Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
Open the PDF for Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition in another window
Includes: Supplementary data
Journal Articles

Abstract 4348: Antitumor activity of Tivantinib (ARQ 197) is due to inhibition of tubulin polymerization in addition to c-Met inhibition.

Ryohei Katayama, Aki Aoyama, Takao Yamori, Jie Qi, Tomoko Ohara, Youngchul Song, Jeffrey A. Engelman, Naoya Fujita
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 4348.
https://doi.org/10.1158/1538-7445.AM2013-4348
Published: 15 April 2013
View article titled, Abstract 4348: Antitumor activity of Tivantinib (ARQ 197) is due to inhibition of tubulin polymerization in addition to c-Met inhibition.
Journal Articles

MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors

Alexa B. Turke, Youngchul Song, Carlotta Costa, Rebecca Cook, Carlos L. Arteaga, John M. Asara, Jeffrey A. Engelman
Journal: Cancer Research
Cancer Res (2012) 72 (13): 3228–3237.
https://doi.org/10.1158/0008-5472.CAN-11-3747
Published: 01 July 2012
View article titled, MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
Open the PDF for MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors in another window
Includes: Supplementary data
Journal Articles

Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer

Xuemei Yang, Alexa B. Turke, Jie Qi, Youngchul Song, Brent N. Rexer, Todd W. Miller, Pasi A. Jänne, Carlos L. Arteaga, Lewis C. Cantley, Jeffrey A. Engelman, John M. Asara
Journal: Cancer Research
Cancer Res (2011) 71 (18): 5965–5975.
https://doi.org/10.1158/0008-5472.CAN-11-0445
Published: 13 September 2011
View article titled, Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer
Open the PDF for Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 956: Receptor tyrosine kinases, not KRAS, activate PI3K in KRAS mutant colorectal cancers

Hiromichi Ebi, Ryan B. Corcoran, Anurag Singh, Zhao Chen, Youngchul Song, Eugene Lifshits, David P. Ryan, Jeffrey A. Meyerhardt, Cyril Benes, Jeffrey Settleman, Lewis C. Cantley, Kwok-Kin Wong, Jeffrey A. Engelman
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 956.
https://doi.org/10.1158/1538-7445.AM2011-956
Published: 15 April 2011
View article titled, Abstract 956: Receptor tyrosine kinases, not KRAS, activate PI3K in KRAS mutant colorectal cancers
Journal Articles

An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation

Birgit Schoeberl, Anthony C. Faber, Danan Li, Mei-Chih Liang, Katherine Crosby, Matthew Onsum, Olga Burenkova, Emily Pace, Zandra Walton, Lin Nie, Aaron Fulgham, Youngchul Song, Ulrik B. Nielsen, Jeffrey A. Engelman, Kwok-Kin Wong
Journal: Cancer Research
Cancer Res (2010) 70 (6): 2485–2494.
https://doi.org/10.1158/0008-5472.CAN-09-3145
Published: 14 March 2010
View article titled, An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation
Open the PDF for An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation in another window
Includes: Supplementary data
Journal Articles

Abstract #1365: HGF induces transient and stable ligand-independent resistance in gefitinib-sensitive lung cancers

Alexa Turke, Youngchul Song, Neal Lindeman, Eugene Lifshits, Yun Xiao, Charles Lee, Pasi Janne, Jeffrey Engelman
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 1365.
Published: 01 May 2009
View article titled, Abstract #1365: HGF induces transient and stable ligand-independent resistance in gefitinib-sensitive lung cancers